Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncotelic Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical issuer with oncology, rare-disease, AI-enabled research and drug-delivery assets. Recent Form 8-K reports cover material definitive agreements, including the TechForce Robotics joint development and licensing framework for AI-enabled GMP robotic systems using the PDAOAI platform, the completed Lunai Bioworks asset transaction involving nose-to-brain delivery patents, and financing arrangements tied to convertible debt and warrants.
OTLC filings also describe capital-structure and governance matters, including a performance-based restricted stock agreement involving Series A Preferred Stock, common-stock conversion terms, secured-note collateral and warrant issuances. Other filings include annual-results exhibits, late annual-report notices on Form 12b-25, and furnished updates on GMP Bio interests, Sapu Nano's Deciparticle nanomedicine platform, everolimus toxicology data and pipeline disclosures.
Oncotelic Therapeutics’ quarter ended March 31, 2026 shows a small cash position and continued losses alongside a very large non‑cash investment asset. Cash was $63,614 with $20,000 in restricted cash, while the company reported a net loss of $2,193,776, wider than a year earlier.
Total assets were $393,955,039, driven mainly by a Level 3 fair value investment in GMP Bio of $388,000,000 and related deferred tax liability of $111,550,000. Stockholders’ equity was $262,211,541 and total liabilities were $131,743,498, but working capital was negative by about $16.3 million.
Management states there is substantial doubt about the company’s ability to continue as a going concern due to recurring losses, limited funding and negative operating cash flow of about $0.3 million for the quarter. To address this, the company has layered convertible debt, including a new ~${398,333} Mast Hill note, and access to a Mast Hill equity purchase agreement for up to $25 million.
Operationally, the JV with Dragon and GMP Bio continues to prepare Phase 2 and 3 trials for OT‑101 and advance five additional nanoparticle cancer therapies. In March 2026, Oncotelic also signed a joint development, manufacturing and licensing agreement with TechForce Robotics to build AI‑enabled, GMP‑compliant robotic systems for pharmaceutical manufacturing.
Oncotelic Therapeutics, Inc. completed a patent-focused merger and related IP restructurings with Lunai Bioworks and affiliates. A holding company owning a multi‑jurisdictional patent portfolio was merged into a Lunai subsidiary, and Lunai issued eight shares of Series B Convertible Preferred Stock with an aggregate Stated Value of $20,000,000 to Oncotelic and Pelerin.
Oncotelic received five preferred shares with a stated value of $12,500,000 and a perpetual, royalty‑free, exclusive license to exploit the transferred intellectual property in all fields except defined biodefense and Alzheimer’s disease indications. Separately, Autotelic Inc. transferred additional drug and delivery platform assets to Oncotelic in exchange for equity equal to ten percent of Oncotelic’s fully diluted shares, issuable upon a future NYSE/NASDAQ uplisting. Both the merger consideration and the asset transfer were non‑cash transactions and rely on contracts attached as exhibits.
Oncotelic Therapeutics reported FY 2025 net income of about $249M, a sharp turnaround from a net loss of roughly $4.5M in 2024. Basic and diluted earnings were $0.59 per share versus a $0.01 loss per share a year earlier.
The swing was driven mainly by a non-cash gain of about $365.3M from revaluing its investment in joint venture GMP Biotechnology Limited, partly offset by a deferred income tax provision of about $111.6M. The company still reported no product revenue, and operating expenses were modest at roughly $3.2M.
Management highlighted progress across its GMP Bio JV, including six Deciparticle nanoparticle candidates, completion of a Phase 1 OT‑101/IL‑2 trial, a Phase 2/3 OT‑101 pancreatic cancer study, and expansion of its PDAOAI AI platform. They also referenced plans to pursue a potential Hong Kong IPO for the JV and a national exchange uplisting for Oncotelic.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharma company focused on orphan oncology, nanomedicine and AI-enabled drug development. Its core value driver is a joint venture, GMP Biotechnology Limited, where it develops OT-101, an antisense drug targeting TGF-β2, and a six-asset Sapu Nano Deciparticle™ oncology platform.
The JV is advancing OT-101 into late-stage trials for high-grade glioma and pancreatic cancer, while also pursuing pediatric DIPG and coronavirus indications, all supported by multiple orphan and rare pediatric designations. Additional legacy assets include CA4P and OXi4503 vascular disrupting agents and AL-101 intranasal apomorphine for Parkinson’s disease, erectile dysfunction and female sexual dysfunction.
The Sapu Nano arm is developing next-generation nanoparticle formulations such as Sapu-001 (paclitaxel), Sapu-003 (everolimus), Sapu-004 (carboplatin), Sapu-005 (palbociclib) and Sapu-006 (docetaxel), backed by a San Diego GMP manufacturing facility and external partners. The company also scaled its PDAOAI AI platform and robotics partnership to support biomarker discovery, regulatory documentation and automated GMP operations. A preliminary third-party JV pipeline valuation of approximately $2.3 billion underpinned an ASC-compliant fair value increase of about $365.4 million for Oncotelic’s 45% JV stake, though management emphasizes this assessment is non-binding and subject to future adjustments.
Oncotelic Therapeutics entered a Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics on March 31, 2026 to co-develop AI-enabled, GMP-compliant robotic systems for pharmaceutical manufacturing. The product integrates TechForce’s robotic hardware with Oncotelic’s proprietary PDAOAI platform.
All AI-related foreground intellectual property and data generated by the product will be owned exclusively by Oncotelic, while TechForce owns its standalone hardware innovations and jointly developed IP is jointly owned. Commercial revenue terms, including revenue sharing and royalties, will be set later in a separate Commercialization and Licensing Agreement, and neither party may begin revenue-generating activities without mutual written consent.
The agreement uses project-based funding with milestone payments, allows either party to terminate for convenience on 60 days’ notice, and restricts TechForce for 12 months after termination from licensing the jointly developed IP for pharma manufacturing without Oncotelic’s approval. Oncotelic issued a press release on April 2, 2026 announcing the strategic partnership.
Oncotelic Therapeutics, Inc. submitted a Form 12b-25 notifying the SEC that its annual report on Form 10-K for the period ended December 31, 2025 could not be filed on time because the company is still compiling the necessary financial information. The company states it expects to file within the permitted extension period.
Oncotelic Therapeutics, Inc. reported that its minority-owned company Sapu Nano will introduce its Deciparticle™ nanomedicine platform and present its clinical pipeline at BIO-Europe Spring 2026 on March 25, 2026. Sapu Nano has been selected as a Presenting Company at the conference.
The session will feature Deciparticle, a sub-20 nm drug delivery platform designed to optimize tissue distribution, improve pharmacokinetics, and reduce formulation-related toxicities for hydrophobic oncology drugs. Two lead candidates include an intravenous everolimus formulation in Phase 1 clinical trials and an advanced docetaxel formulation entering Phase 1.
The disclosure also reiterates Oncotelic’s broader oncology strategy, including rare pediatric cancer designations through its 45% joint venture GMP Bio and programs such as OT-101, CA4P, OXi 4503, and AL-101 for neurological and sexual health indications, while emphasizing extensive forward-looking statement cautions.
Oncotelic Therapeutics, Inc. filed a current report describing a scientific disclosure rather than a financial event. The company announced that Sapu Nano, an entity in which it holds a minority interest, will present new everolimus toxicology data at the 2026 Society of Toxicology Annual Meeting and ToxExpo in San Diego. The poster, titled “Everolimus Toxicology: Tissue Concentration Effects,” examines how tissue-level exposure to everolimus relates to organ-specific toxic outcomes, extending understanding beyond traditional plasma pharmacokinetics. The work supports development of intravenous and nanoparticle-based formulations designed to better control drug distribution. The presentation is scheduled for March 23, 2026, during the ADME/Toxicokinetics I poster session.
Oncotelic Therapeutics, Inc. entered a Securities Purchase Agreement with Mast Hill Fund, LP and issued a secured convertible promissory note with an aggregate gross principal amount of $398,333.33. The note carries a 10% original issue discount, 10% annual interest and matures around one year after the agreement date, subject to earlier prepayment or default.
The note is convertible into common stock at a fixed price of $0.07 per share, subject to adjustment, and is secured by most company and subsidiary assets, excluding assets tied to its Dragon Overseas Capital joint venture. The company also issued 1,422,613 warrants with a $0.15 exercise price. Proceeds must be used for general working capital under specific restrictions. A registration rights agreement was signed to register shares underlying the note and warrants, which were issued under a private placement exemption.
Oncotelic Therapeutics Chairman and CEO Vuong Trieu reported an award of 4,426 shares of Series A Convertible Preferred Stock on January 22, 2026. The preferred stock is convertible at the holder’s option into 4,426,000 shares of common stock on a one-for-one thousand basis and was issued at a stated price of $0.00 per share as compensation for achieving performance milestones under a Restricted Stock Agreement dated January 21, 2026. Following this grant, Dr. Trieu beneficially owns 8,491 shares of the Series A Convertible Preferred Stock directly.